Vieri Scotti
About
Vieri Scotti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Vieri Scotti has authored 109 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Vieri Scotti's work include Lung Cancer Treatments and Mutations (28 papers), Breast Cancer Treatment Studies (27 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Vieri Scotti is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Breast Cancer Treatment Studies (27 papers) and Lung Cancer Diagnosis and Treatment (24 papers). Vieri Scotti collaborates with scholars based in Italy, United States and France. Vieri Scotti's co-authors include Lorenzo Livi, Icro Meattini, Simonetta Bianchi, Calogero Saieva, Gabriele Simontacchi, L. Marrazzo, Jacopo Nori, Lorenzo Orzalesi, Luis Sanchez and Isacco Desideri and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
Vieri Scotti
106 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Vieri Scotti Italy | 21 | 874 | 764 | 516 | 382 | 338 | 109 | 1.6k | ||
| Margreet H.A. Baaijens Netherlands | 17 | 869 1.0× | 749 1.0× | 527 1.0× | 368 1.0× | 605 1.8× | 22 | 2.5k | ||
| Welela Tereffe United States | 26 | 1.3k 1.5× | 776 1.0× | 310 0.6× | 326 0.9× | 726 2.1× | 72 | 1.9k | ||
| J. Frank Wilson United States | 23 | 584 0.7× | 519 0.7× | 404 0.8× | 389 1.0× | 271 0.8× | 81 | 1.6k | ||
| Maurice J.C. van der Sangen Netherlands | 25 | 1.1k 1.3× | 945 1.2× | 857 1.7× | 261 0.7× | 558 1.7× | 80 | 2.3k | ||
| Penny R. Anderson United States | 26 | 1.2k 1.3× | 675 0.9× | 488 0.9× | 559 1.5× | 519 1.5× | 87 | 2.4k | ||
| James P. Morden United Kingdom | 17 | 658 0.8× | 848 1.1× | 1.1k 2.1× | 494 1.3× | 152 0.4× | 51 | 2.6k | ||
| Wendy Shelley Canada | 19 | 1.3k 1.5× | 789 1.0× | 369 0.7× | 518 1.4× | 586 1.7× | 25 | 2.2k | ||
| C. Lemanski France | 31 | 821 0.9× | 1.1k 1.5× | 1.1k 2.1× | 400 1.0× | 455 1.3× | 138 | 2.9k | ||
| H.J. Dobbs United Kingdom | 12 | 861 1.0× | 502 0.7× | 286 0.6× | 424 1.1× | 337 1.0× | 23 | 1.5k | ||
| Nhu Le Canada | 4 | 1.7k 1.9× | 669 0.9× | 269 0.5× | 327 0.9× | 882 2.6× | 6 | 2.0k |
Countries citing papers authored by Vieri Scotti
Since
Specialization
Citations
This map shows the geographic impact of Vieri Scotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vieri Scotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vieri Scotti more than expected).
Fields of papers citing papers by Vieri Scotti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vieri Scotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vieri Scotti. The network helps show where Vieri Scotti may publish in the future.
Co-authorship network of co-authors of Vieri Scotti
This figure shows the co-authorship network connecting the top 25 collaborators of Vieri Scotti. A scholar is included among the top collaborators of Vieri Scotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vieri Scotti. Vieri Scotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gelmini, Stefania, Irene Mancini, Camilla Comin, et al.. (2025). Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience. International Journal of Molecular Sciences. 26(2). 611–611.
2.
Ciammella, Patrizia, Francesco Iori, Paolo Borghetti, et al.. (2025). Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial). Lung Cancer. 207. 108718–108718.
3.
Bruni, Alessio, Vieri Scotti, Federica Bertolini, et al.. (2024). Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Current Oncology. 31(11). 6791–6802.
4.
Becherini, Carlotta, Viola Salvestrini, Isacco Desideri, et al.. (2024). Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature. La radiologia medica. 129(3). 457–466.
5.
Salvestrini, Viola, Marco Banini, Mauro Loi, et al.. (2024). Recent Advances and Current Challenges in Stereotactic Body Radiotherapy for Ultra-Central Lung Tumors. Cancers. 16(24). 4135–4135.
6.
Camerini, Andrea, Francesca Mazzoni, Vieri Scotti, et al.. (2024). Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 13(13). 3642–3642.
7.
Banini, Marco, Viola Salvestrini, Alessandra Vultaggio, et al.. (2023). Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review. Current Oncology. 30(7). 6699–6707.
8.
Cameli, Paolo, Paola Faverio, Stefania Marsili, et al.. (2022). Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. Life. 12(8). 1149–1149.
9.
Salvestrini, Viola, Carlotta Becherini, Isacco Desideri, et al.. (2022). The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma. La radiologia medica. 127(8). 866–871.
10.
Giaj‐Levra, Niccolò, Paolo Borghetti, Alessio Bruni, et al.. (2020). Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy. 20(5). 387–402.
11.
Desideri, Isacco, Giulio Francolini, Lucia Pia Ciccone, et al.. (2020). Impact of COVID-19 on patient–doctor interaction in a complex radiation therapy facility. Supportive Care in Cancer. 29(6). 2931–2937.
12.
Rastrelli, Giulia, Isacco Desideri, Vieri Scotti, et al.. (2019). Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. Journal of Endocrinological Investigation. 43(3). 337–345.
13.
Livi, Lorenzo, Vieri Scotti, Isacco Desideri, et al.. (2019). Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. European Journal of Cancer. 108. 100–110.
14.
Meattini, Icro, Isacco Desideri, Vieri Scotti, Gabriele Simontacchi, & Lorenzo Livi. (2018). Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. The Breast. 42. 1–2.
15.
Campiglio, Manuela, Rosaria Bufalino, Elisa Ferri, et al.. (2013). Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Research and Treatment. 141(1). 101–110.
16.
Meattini, Icro, Lorenzo Livi, Davide Franceschini, et al.. (2013). Role of radiotherapy boost in women with ductal carcinoma in situ: A single-center experience in a series of 389 patients. European Journal of Surgical Oncology. 39(6). 613–618.
17.
Meattini, Icro, Lorenzo Livi, Calogero Saieva, et al.. (2012). Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience. Journal of Chemotherapy. 24(5). 279–284.
18.
Meattini, Icro, Lorenzo Livi, Davide Franceschini, et al.. (2012). Treatment of invasive male breast cancer: a 40-year single-institution experience. La radiologia medica. 118(3). 476–486.
19.
Livi, Lorenzo, Icro Meattini, Vieri Scotti, et al.. (2011). Concomitant adjuvant chemo-radiation therapy with anthracyclinebased regimens in breast cancer: a single centre experience. La radiologia medica. 116(7). 1050–1058.
20.
Livi, Lorenzo, Calogero Saieva, Simona Borghesi, et al.. (2009). Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer. Journal of Chemotherapy. 21(5). 558–565.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Margreet H.A. Baaijens Breakdown of academic impact, for papers by Welela Tereffe Breakdown of academic impact, for papers by J. Frank Wilson Breakdown of academic impact, for papers by Maurice J.C. van der Sangen Breakdown of academic impact, for papers by Penny R. Anderson Breakdown of academic impact, for papers by James P. Morden Breakdown of academic impact, for papers by Wendy Shelley Breakdown of academic impact, for papers by C. Lemanski Breakdown of academic impact, for papers by H.J. Dobbs Breakdown of academic impact, for papers by Nhu Le